Methotrexate (MTX) is a nonbiological disease-modifying antirheumatic drug that has shown both a good control of clinical disease and a good safety. Usually drug-drug interactions (DDIs) represent the most limiting factor during the clinical management of any disease, in particular when several drugs are coadministered to treat the same disease. In this paper, we report the interactions among MTX and the other drugs commonly used in the management of rheumatoid arthritis. Using Medline, PubMed, Embase, Cochrane libraries, and Reference lists, we searched for the articles published until June 30, 2012, and we reported the most common DDIs between MTX and antirheumatic drugs. In particular, clinically relevant DDIs have been described during the treatment with MTX and NSAIDs, for example, diclofenac, indomethacin, or COX-2 inhibitors, and between MTX and prednisone or immunosuppressant drugs (e.g., leflunomide and cyclosporine). Finally, an increase in the risk of infections has been recorded during the combination treatment with MTX plus antitumor necrosis factor-α agents. In conclusion, during the treatment with MTX, DDIs play an important role in both the development of ADRs and therapeutic failure. © 2013 Marinella Patanè et al.

Interactions among low dose of methotrexate and drugs used in the treatment of rheumatoid arthritis / Patane M.; Ciriaco M.; Chimirri S.; Ursini F.; Naty S.; Grembiale R.D.; Gallelli L.; De Sarro G.; Russo E.. - In: ADVANCES IN PHARMACOLOGICAL SCIENCES. - ISSN 1687-6334. - STAMPA. - 2013:(2013), pp. 313858.1-313858.8. [10.1155/2013/313858]

Interactions among low dose of methotrexate and drugs used in the treatment of rheumatoid arthritis

Ursini F.;
2013

Abstract

Methotrexate (MTX) is a nonbiological disease-modifying antirheumatic drug that has shown both a good control of clinical disease and a good safety. Usually drug-drug interactions (DDIs) represent the most limiting factor during the clinical management of any disease, in particular when several drugs are coadministered to treat the same disease. In this paper, we report the interactions among MTX and the other drugs commonly used in the management of rheumatoid arthritis. Using Medline, PubMed, Embase, Cochrane libraries, and Reference lists, we searched for the articles published until June 30, 2012, and we reported the most common DDIs between MTX and antirheumatic drugs. In particular, clinically relevant DDIs have been described during the treatment with MTX and NSAIDs, for example, diclofenac, indomethacin, or COX-2 inhibitors, and between MTX and prednisone or immunosuppressant drugs (e.g., leflunomide and cyclosporine). Finally, an increase in the risk of infections has been recorded during the combination treatment with MTX plus antitumor necrosis factor-α agents. In conclusion, during the treatment with MTX, DDIs play an important role in both the development of ADRs and therapeutic failure. © 2013 Marinella Patanè et al.
2013
Interactions among low dose of methotrexate and drugs used in the treatment of rheumatoid arthritis / Patane M.; Ciriaco M.; Chimirri S.; Ursini F.; Naty S.; Grembiale R.D.; Gallelli L.; De Sarro G.; Russo E.. - In: ADVANCES IN PHARMACOLOGICAL SCIENCES. - ISSN 1687-6334. - STAMPA. - 2013:(2013), pp. 313858.1-313858.8. [10.1155/2013/313858]
Patane M.; Ciriaco M.; Chimirri S.; Ursini F.; Naty S.; Grembiale R.D.; Gallelli L.; De Sarro G.; Russo E.
File in questo prodotto:
Eventuali allegati, non sono esposti

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11585/781897
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 37
  • ???jsp.display-item.citation.isi??? ND
social impact